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Adoptive cellular therapy using chimeric antigen receptor T-cell (CAR-T) therapy is currently being evaluated in patients with relapsed /refractory multiple myeloma (MM). The majority of CAR-T cell pro-
grams now being tested in clinical trials are targeting B-cell maturation anti-
gen. Several recent phase I / II trials show promising preliminary results in
patients with MM progressing on proteasome inhibitors, immunomodula-
tory drugs  and monoclonal antibodies targeting CD38. CAR-T cell therapy
is a potentially life-threatening strategy that can only be administered in
experienced centers. For the moment, CAR-T cell therapy for MM is still
experimental, but once this strategy has been approved in relapsed/refrac-
tory MM, it will become one of the most important indications for this
therapy in Europe and world-wide. This manuscript proposes practical con-
siderations for the use of CAR-T cell therapy in MM, and discusses several
important issues for its future development.
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ABSTRACT
Introduction
In recent years, the development of immunotherapy has revolutionized the treat-
ment of cancer, including hematologic malignancies and multiple myeloma (MM).1
Therapeutic agents which induce the autologous immune cells to mediate tumor
cell killing and to overcome the immunosuppressive mechanisms of the tumor
microenvironment may improve clinical outcome. In this setting, adoptive cellular
therapy using chimeric antigen receptor (CAR-T), a redirection strategy of T cells
with the goal of increasing the frequency of tumor-directed and functionally active
T cells targeting specifically expressed antigens on myeloma cells, is currently being
evaluated in patients with MM.2
CAR-T cell therapy has already been approved by the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) for the treatment
of relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and
young adult patients, and for diffuse large B-cell lymphoma (DLBCL). At the time of
writing (2019), it is under evaluation for the treatment of relapsed / refractory MM
(RRMM) in phase I / II trials3 and phase III trials sponsored by different pharmaceu-
tical companies have just started in these patients. Therefore, CAR-T cell therapy will
not have been approved for the treatment of MM by the end of 2019.
B-cell maturation antigen (BCMA, also named TNFRSF17 or CD269) belongs to
the family of tumor necrosis factors. It was initially identified on the cell surface of
the normal and malignant plasma cells and B lympho-
cytes.4 BCMA is also expressed on myeloma cell lines.5
Considering the strong and fairly homogeneous expres-
sion of the BCMA receptor on malignant plasma cells and
its important mechanism of action, BCMA represent an
ideal therapeutic target for CAR-T cell therapy.6 Indeed,
the majority of CAR-T cell programs currently being test-
ed in clinical trials are targeting BCMA. Other targets on
MM cells are under early preclinical development. The
first 'in human' clinical trial of CAR-T cells targeting
BCMA that showed anti-myeloma activity was published
in 2016.7 Several recent phase I / II trials show promising
preliminary results in MM patients progressing on protea-
some inhibitors, immunomodulatory drugs (IMiD) and
monoclonal antibodies targeting CD38.8-9 In this situation
of unmet medical need, high response rates and minimal
residual disease (MRD) negativity are achieved, and the
median progression-free survival (PFS) in responding
patients is >15 months.5,8,9 Nevertheless, no plateau has
been observed on PFS curves, indicating the low probabil-
ity for cure, at least in these heavily pretreated patients.
CAR-T cell therapy is a potentially life-threatening strate-
gy that that can only be administered in experienced cen-
ters. The major toxicity in MM patients is the cytokine
release syndrome (CRS) that may require short hospital-
ization in intensive care units.5,6,10 Neurotoxicity seems far
less frequent and severe when compared to CAR-T cell
therapy for B-ALL and DLBCL.5-6,10 Overall, fewer than 100
patients with RRMM treated with CAR-T cells targeting
BCMA have been reported. These patients were highly
selected, had refractory disease at the time of entry into
clinical trials, while still having good clinical status, and
were able to remain without any therapeutic intervention
for 4-5 weeks during the manufacturing process of CAR-
T cells.
CAR-T cell therapy is by far one of the most expensive
therapies for hematologic malignancies.
Practical considerations
Once CAR-T cell therapy is approved in RRMM, it will
become one of the most important indications for this
strategy in Europe and world-wide.
For the moment, CAR-T cell therapy for MM is still
experimental.7-8 Clinical programs need to be developed
under the scientific guidance of the disease experts and co-
operative groups in selected centers. 
The results of large company-sponsored phase II trials
using CAR-T cells infused at the optimal dose are expect-
ed at the end of 2019. Several phase III trials have just
started (2019), testing CAR-T cells either in very advanced
patients or earlier in the course of the disease, especially in
high-risk patients. Very few academic trials using CAR-T
cell therapy are currently ongoing. The CAR-T cell thera-
py is different from allogeneic stem cell transplantation
(allo-SCT).5-6 There is no scientific reason to support the
experience on allo-SCT as the only prerequisite for the
identification / selection of centers accredited for CAR-T
cell therapy. Toxicity of CAR-T cells is different from that
of allo-SCT:  the use of a protected environment is not
needed, graft-versus-host disease (GvHD) is by definition
absent. Given this, one of the most common links
between allo-SCT and the CAR-T programs is the aphere-
sis process that will require pertinent accreditations and/or
certifications. Experience in hematopoietic transplantation
(allo and/or auto) is very important, and expertise in cell
therapy manipulation is critical. CAR-T therapy should be
performed by a team of experts in MM and in cellular
therapy, which curently includes experts in the specific
disease and in autologous and/or allogeneic transplanta-
tion, in close collaboration with, among others, intensive
care specialists and neurologists, together with a well
trained nursing team.
CAR-T cell therapy for MM will potentially become a
highly-specialized medication, associated with very high
costs. Indications for the use of CAR-T therapy should be
clearly defined by experts in MM, if possible through
international guidelines. A European consensus, defined
by co-operative groups, national societies of hematology,
the European Myeloma Network (EMN) and the
European Hematology Association (EHA) should be pro-
posed to national and European authorities.
The creation of a list of centers of excellence in each
European country, certified for CAR-T cell therapy and
other advanced immunotherapies, based on disease area
and expertise is of the utmost importance. This list may
be drawn up by national societies and national health
authorities, in the overarching framework of the main
European societies, including the specific myeloma groups
in each country as well as the European Myeloma
Network and EHA.  
A specific European registry for the follow up of
patients receiving CAR-T cell therapy including treatment
indications, response data, previous and subsequent lines
of therapy and treatments, safety and long-term follow up
(e.g. to monitor for insertion mutagenesis after genetic
modification of T cells) must be compiled. As all data from
patients treated with CAR-T cells will be registered on the
database of the European Group for Blood and Marrow
Transplantation (EBMT), it will be mandatory to build a
working group combining myeloma experts and national
co-operative groups to ensure the accuracy of the data
submitted. The presence of disease experts in this group is
key to generate scientific knowledge and to propose new
studies. This registry should also collect data from other
types of innovative and expensive immunotherapies in
order to compare their safety and efficacy. 
Important issues in the near future
CAR-T cell therapy is still an experimental therapy,
mainly developed by pharmaceutical companies.
Academic research programs are urgently needed to
improve efficacy and safety, either working with biotech
companies or big pharma or independently. A particular
focus should be to improve persistence of CAR-T cells,
avoid antigen loss and reduce CRS/neurotoxicity.10,11 This
is nothing new in myeloma, a disease in which the close
collaboration between the pharmaceutical companies and
the European co-operative group has led to an improve-
ment in outcomes.  
The definition of the optimal use of CAR-T cells, includ-
ing very precise indications and approval, requires the
guidance of myeloma experts. For example, when is a
patient to be considered a candidate for CAR-T cell thera-
py? What is the optimal bridging therapy? Does this also
depend on renal function? What are the alternative treat-
ment options? Such questions clearly indicate that the
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development of guidelines is mandatory, especially in the
current complex therapeutic landscape of this disease. 
It is crucial that priorities be clearly defined. Academic
programs must be developed in order to: (i) reduce the
high cost of CAR-T cells proposed by pharmaceutical
companies; (ii) increase academic knowledge on CAR-T
cell therapy; (iii) propose new collaborations with phar-
maceutical companies; and (iv) design EU clinical trials
based on the combination of CAR-T with current or new
anti-myeloma strategies.
Educational programs for the use of CAR-T cells should
be developed through the different European societies,
such as the EMN, ESH, EHA, international societies like
the International Myeloma Society (IMS), and the national
societies or co-operative groups.
The definition of consensus guidelines and educational
programs for autologous CAR-T cell therapy could be
expanded to other immunotherapeutic approaches, such
as bispecific antibodies, conjugates, NK-cell therapy or
allo-CAR-T. Hopefully, in the near future,  several strate-
gies targeting BCMA and other plasma cell antigens will
become available for the treatment of myeloma patients.
The right time for each myeloma patient to use a CART
or a bispecific antibody or antibody drug conjugate
should be defined by clinical experts, and this will
require in-depth knowledge of the disease. Educational
programs under the guidance of myeloma experts will
not only help improve the outcome of our patients, but
also contribute to a more efficient use of the resources
available. 
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